Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Tim Demuth"'
Autor:
Jan H.M. Schellens, Tim Demuth, Kati Maharry, Eugene Tan, Savina Jaeger, Arkendu Chatterjee, Emin Avsar, Zev A. Wainberg, Heinz-Josef Lenz, Rona Yaeger, Sunil Sharma, Ferry A.L.M. Eskens, Jason E. Faris, Martijn P. Lolkema, Yasuhide Yamada, Jean-Pierre Delord, Takayuki Yoshino, Martin Schuler, Anna Spreafico, Johanna C. Bendell, Elena Elez, Josep Tabernero, Robin M.J.M. van Geel
Table S1. Pharmacokinetic parameters of encorafenib and alpelisib in patients at steady state (cycle 2 day 1). Table S2. Criteria for defining dose-limited toxicities. Supplementary Figure 1. Radiological images of response for a patient treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1341dd8cec12a541df23cf9cbed4ad9b
https://doi.org/10.1158/2159-8290.22532039
https://doi.org/10.1158/2159-8290.22532039
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
(A) Average body weight of mice treated with each BRAF inhibitor in the experiment depicted in Figure 1C; (B) Encorafenib plasma exposure in mice following the last dose from the experiment depicted in Figure 1C. To estimate daily exposure on the BID
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e582a2e6528fa79c1c59d17f45ea091
https://doi.org/10.1158/1078-0432.22467995
https://doi.org/10.1158/1078-0432.22467995
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. We evaluated encorafenib in a phase I study in patients with BRAFi treatment-naïve and pretreated BRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d33fd78b0f824a6d521ad7699f44e3c
https://doi.org/10.1158/1078-0432.c.6526808
https://doi.org/10.1158/1078-0432.c.6526808
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Biochemical and cellular potency of encorafenib, dabrafenib, and vemurafenib in biochemical and cell-based assays. Purified BRAF V600E kinase domain was used in the biochemical experiments, using kinase-dead MEK1 as a substrate and a phosphorylated M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e51957f9f54ec77b6c8a756ef60a095
https://doi.org/10.1158/1078-0432.22467989
https://doi.org/10.1158/1078-0432.22467989
Autor:
Karuppiah Kannan, Nancy Kohl, Murray O. Robinson, M. Isabel Chiu, Steve Clark, Tim Demuth, John F. Reilly, Christopher Winter, Chris Ware, Joerg Heyer, Jie Lin, Wenping Sun, Lingxin Kong, Carol Meeske, Sireesha Yalavarthi, Ruojie Wang, Pradip K. Majumder, Chun Cheng, James W. Watters
Notch pathway signaling plays a fundamental role in normal biological processes and is frequently deregulated in many cancers. Although several hypotheses regarding cancer subpopulations most likely to respond to therapies targeting the Notch pathway
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bde16d7f424b454e060ac021a814bec6
https://doi.org/10.1158/0008-5472.c.6500225.v1
https://doi.org/10.1158/0008-5472.c.6500225.v1
Autor:
Karuppiah Kannan, Nancy Kohl, Murray O. Robinson, M. Isabel Chiu, Steve Clark, Tim Demuth, John F. Reilly, Christopher Winter, Chris Ware, Joerg Heyer, Jie Lin, Wenping Sun, Lingxin Kong, Carol Meeske, Sireesha Yalavarthi, Ruojie Wang, Pradip K. Majumder, Chun Cheng, James W. Watters
Supplementary Figure 1, Table 1 from De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1421828eff0a2738a5338061117994b7
https://doi.org/10.1158/0008-5472.22382498.v1
https://doi.org/10.1158/0008-5472.22382498.v1
Publikováno v:
Cancer Research. 83:CT154-CT154
Introduction: Cinrebafusp alfa is a first-in-class bispecific antibody-Anticalin® fusion protein that targets HER2 and the costimulatory receptor 4-1BB, leading to enhanced activation of T cells in the tumor, while avoiding liver toxicity. In a Phas
Autor:
Christiane Jungels, Nuria Kotecki, Emiliano Calvo, Elena Garralda, Timothy Price, Xiaojiang Zahn, Atif Abbas, Lisa Mahnke, Winrich Rauschning, Aizea Morales-Kastresana, Lucia Pattarini, Birgit Bossenmaier, Alix Scholer-Dahirel, Tim Demuth, Julie Legrande
Publikováno v:
Cancer Research. 82:CT255-CT255
PRS-344/S095012 is a bispecific antibody-Anticalin® fusion protein targeting PD-L1 and 4-1BB. It is designed to block the PD-1/PD-L1 axis and localize 4-1BB co-stimulation to PD-L1-positive tumor microenvironment (TME) or tumor draining lymph nodes
Autor:
Sarina A. Piha-Paul, Mukul Gupta, Do-Youn Oh, Yeul Hong Kim, Sun Young Rha, Yoon-Koo Kang, Marc Diez Garcia, Tania Fleitas Kanonnikoff, Virginia Arrazubi Arrula, Kayti Aviano, Tim Demuth, Geoffrey Ku
Publikováno v:
Cancer Research. 82:CT122-CT122
Background: For patients (pts) with HER2-overexpressing metastatic gastric cancer, trastuzumab + chemotherapy +/- pembrolizumab is a standard first-line option but only provides an incremental overall survival (OS) benefit vs chemotherapy. Anticalin